LNAI Stock — Lunai Bioworks Inc.

Latest documents

what the company just published, in one sentence each

2026

Oct 23

Current report 8-K Events of Oct 16

Delisting notice or listing transfer, Director or officer change, or executive pay, Regulation FD disclosure, Other events

Lunai Bioworks Inc. will voluntarily delist after Nasdaq cited a $(9,024,946) stockholders’ deficit, expecting delisting on or about November 12, 2026. CFO Nathen Fuentes resigned immediately, and no successor or interim principal financial officer was appointed.

Oct 13

Annual report 10-K FY2026, ended Jun 30

Annual report for FY2026

Lunai Bioworks Inc. completed the Neurobridge IP Holdings Incorporated acquisition on May 1, 2026 for Series B preferred stock with an aggregate stated value of $20.0 million. It reported a net loss of $3,562,479 for fiscal 2026 and less than one month of available cash as of October 13, 2026.

Revenue $51.99K Net loss $3.56M Diluted EPS -$1.06

Read from the MD&A section

Oct 9

Current report 8-K

Other events

On October 9, 2026, Lunai Bioworks, Inc. asked Nasdaq to immediately suspend trading in its common stock, citing records from pending litigation; Nasdaq had not decided, and the request did not halt trading.

Sep 29

Late filing notice NT 10-K

Late filing notice

Lunai Bioworks Inc. anticipates a net loss of approximately $3.2 million for fiscal 2026, versus approximately $178.0 million for fiscal 2025, and plans to file its annual report by the fifteenth calendar day after the prescribed due date.

Jun 17

Current report 8-K

Other events AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$3.56M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

-16,729.4%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+52.5%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

2.3%

Latest settlement · 1.0 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

· $31,558 −$399,072 '13 Q3 · $925 −$371,546 '14 Q1 · $42,525 −$421,776 '16 Q2 · $0 −$2.96M '18 Q3 LATEST · $20,942 −$2.57M '26 Q3

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 28.2 · fear Equity put/call 0.89

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −94%

below

Price vs 50-day avg −90%

below

RSI (14) 13

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −88%

trailing

6-month return −94%

trailing

YTD return −98%

this year

Relative strength −98%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $2 › 200d $3 — 200d above 50d

Institutional flow Distributing

3 of 16 funds reported for Sep 30 · net -109 sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.31% of shares out · ▼ -21.4% MoM · 1.0 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr low

16 holders — near 1-yr low, contrarian setup

Squeeze score 41

elevated · 0–100

Fundamentals

Fair

Gross margin 72%

EPS growth +99%

Y/Y

Free cash flow $-5.3M

Balance sheet $79.5K

net debt

Quant / Vol

risk profile

Very High

Volatility 232%

annualized · 1-yr

Max drawdown −99%

past year

ATR 98.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−94% Bearish

Price vs 50-day avg

−90% Bearish

RSI (14)

13 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $2 › 200d $3 — 200d above 50d

Institutional flow Distributing

3 of 16 funds reported for Sep 30 · net -109 sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.31% of shares out · ▼ -21.4% MoM · 1.0 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr low

16 holders — near 1-yr low, contrarian setup

Price context

position in its 52-week range

Range low $0 Now $0 · 0% Range high $12

vs 200-day avg -94% vs 50-day avg -90%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
LNAI Lunai Bioworks Inc. this stock	$829,677	—	—	—	2.3%
VRTX Vertex Pharmaceuticals Inc	$138.71B	+20.7%	+46.2%	35.2	1.7%
MRNA Moderna, Inc.	$96.40B	+762.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$93.82B	+17.2%	+20.8%	20.1	2.1%
CSLLY Csl Ltd	$67.11B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

17

% held: 3.9%
Reported: 3 of 16
Top holder: Ground Swell Capital, LLC

Held Float

View

Held by Funds

Fund positions

5

View

Short & Settlement

Short Interest Falling

Shares short

116.5K

Days to cover: 1.0d
Change: -31.6K sh

View

Short Volume

Short vol %

37%

As of: Oct 29, 2026

Short Total

View

Fails to Deliver

FTD shares

2.3K

Value: $4.1K
As of: Sep 30, 2026

View

Off-Exchange

Off-exchange %

58.2%

Week of: Sep 28, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Nov 8, 2022

View

Financials

Revenue (FY)

$52.0K

Net income (FY): $-3.6M
EPS diluted: $-1.06

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 23, 2026
This year: 22

Lunai Bioworks Inc. will voluntarily delist after Nasdaq cited a $(9,024,946) stockholders’ deficit, expecting delisting on or about November 12, 2026. CFO Nathen Fuentes resigned immediately, and no successor or interim principal financial officer was appointed.

View

Proposed Sales

Value

$1.7M

Shares: 1.2M
Filed: Jun 11, 2024

View

Exempt Offerings

Offering

$106.8M

Filed: Feb 23, 2024

View

Earnings & Events

Investor Relations

	5D	20D	120D	MTD	YTD
LNAI	-64.9%	-88.1%	-93.8%	-88.8%	-97.7%
SPY	+0.7%	+0.7%	+4.3%	+0.9%	+12.8%
vs SPY	-65.7%	-88.8%	-98.1%	-89.7%	-110.5%

LNAI · Lunai Bioworks Inc.

Price & Indicators

Latest documents

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance